ImmunityBio (NASDAQ:IBRX) Shares Up 2.4% – Still a Buy?

ImmunityBio, Inc. (NASDAQ:IBRX) shares traded up 2.4% during mid-day trading on Friday . The stock traded as high as $9.80 and last traded at $9.78. 28,541,428 shares traded hands during trading, a decline of 37% from the average session volume of 45,534,469 shares. The stock had previously closed at $9.55.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio announced completion of enrollment in its pivotal randomized Phase 2 trial of ANKTIVA plus BCG vs BCG alone in BCG‑naïve NMIBC CIS — early completion reduces timeline uncertainty for a potential label‑expanding readout and supports commercial upside for ANKTIVA. Article Title
• Positive Sentiment: Analyst/valuation commentary highlights trial progress and strong ANKTIVA commercial momentum — positive narratives that can support higher forward earnings expectations and investor confidence. Article Title
• Neutral Sentiment: ImmunityBio will host a business update and review FY‑2025 financial results on March 3 — the call could drive volatility depending on revenue, guidance, and clinical updates management provides. Article Title
• Neutral Sentiment: HC Wainwright published a Q1 earnings forecast for ImmunityBio — analyst forecasts and any accompanying model changes will influence near‑term analyst sentiment and target‑price revisions. Article Title
• Negative Sentiment: Director Barry Simon sold 75,000 shares at an average price of $12.01 (disclosed Feb 24) — insider selling can be interpreted by some investors as a signal to reduce exposure, contributing to downward pressure. Article Title
• Negative Sentiment: Reports cite significant intraday profit‑taking (one article notes a ~17% drop after an intraday high) and coverage pointing to a ~7% decline — these articles reflect short‑term selling and headline‑driven volatility that can amplify swings in the stock. Article Title Article Title

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on IBRX shares. Piper Sandler increased their target price on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price objective on shares of ImmunityBio in a research report on Monday. HC Wainwright raised their target price on shares of ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a report on Monday. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.60.

ImmunityBio Stock Up 2.4%

The firm has a market capitalization of $10.05 billion, a price-to-earnings ratio of -25.74 and a beta of 0.16. The company has a 50-day moving average price of $5.12 and a 200-day moving average price of $3.32.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. As a group, analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Insider Transactions at ImmunityBio

In other news, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Barry J. Simon sold 75,000 shares of the business’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total value of $900,750.00. Following the completion of the sale, the director directly owned 2,850,821 shares in the company, valued at $34,238,360.21. This represents a 2.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 501,967 shares of company stock worth $4,466,412. Company insiders own 69.48% of the company’s stock.

Institutional Investors Weigh In On ImmunityBio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of ImmunityBio by 18.5% during the 4th quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock valued at $64,899,000 after purchasing an additional 5,122,052 shares in the last quarter. State Street Corp lifted its stake in ImmunityBio by 45.4% during the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after purchasing an additional 5,139,890 shares during the last quarter. Geode Capital Management LLC boosted its holdings in ImmunityBio by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock worth $15,684,000 after buying an additional 1,030,113 shares in the last quarter. Armistice Capital LLC acquired a new position in ImmunityBio in the second quarter worth approximately $20,497,000. Finally, Heights Capital Management Inc. acquired a new position in ImmunityBio in the third quarter worth approximately $16,152,000. 8.58% of the stock is currently owned by institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.